Professor Flewitt and academic urological surgeon Mr Vincent Gnanapragasam, who co-leads the CRUK Cambridge Centre Urological Malignancies Programme, are using FBAR sensor technology in a new PSA test.
FBARs are strips on a chip that measure the weight of different molecules. They can be used to measure the amount of different subtypes of PSA in a blood sample to identify more accurately whether or not the patient has prostate cancer – a reliable and cost-effective test, using bio-sensor technology, to be delivered in a primary care setting within the goal of the next five years.
